Trial · NCT03824938

Aspirin for Exercise in Multiple Sclerosis (ASPIRE)

NCT03824938, Phase 3, Completed, Columbia University; results first posted 2023-10-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Aspirin for Exercise in Multiple Sclerosis (ASPIRE). Trials, record NCT03824938. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03824938

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Aspirin for Exercise in Multiple Sclerosis (ASPIRE)
NCT number: NCT03824938
Status: Completed
Phases: Phase 3
Enrollment: 60 participants, actual
Lead sponsor: Columbia University
Conditions: Multiple Sclerosis
Interventions: Aspirin 650mg Oral Capsule, Acetaminophen Tablet 650mg, Placebo
First posted: 2019-01-31
Last updated: 2023-10-27
Results first posted: 2023-10-27

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Time-to-exhaustion	from start of exercise test until self-reported exhaustion, up to 30 minutes	Duration of time exercising before reaching peak exertion, defined as cadence drop below 40 revolutions per minute (RPM) for \>/= 5 seconds, or patient reaches volitional exhaustion in accordance with American Thoracic Society standard test termination criteria.
Primary	Exercise-induced Body Temperature Change	from start of exercise test until self-reported exhaustion, up to 30 minutes	Change in body temperature from pre- to post- maximal exercise test.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Time-to-exhaustion	from start of exercise test until self-reported exhaustion, up to 30 minutes		seconds	MEAN
PRIMARY	Exercise-induced Body Temperature Change	from start of exercise test until self-reported exhaustion, up to 30 minutes		degrees Fahrenheit	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Time-to-exhaustion	Placebo	551.7	Standard Deviation 78.4	seconds
Time-to-exhaustion	Aspirin	331.6	Standard Deviation 76.6	seconds
Time-to-exhaustion	Acetaminophen	578.2	Standard Deviation 82.1	seconds
Exercise-induced Body Temperature Change	Placebo	0.68	Standard Deviation 0.35	degrees Fahrenheit
Exercise-induced Body Temperature Change	Aspirin	0.006	Standard Deviation 0.32	degrees Fahrenheit
Exercise-induced Body Temperature Change	Acetaminophen	0.31	Standard Deviation 0.35	degrees Fahrenheit

Source ClinicalTrials.gov

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo First, Then Aspirin, Then Acetaminophen	7
Overall Study	STARTED	Placebo First, Then Acetaminophen, Then Aspirin	8
Overall Study	STARTED	Aspirin First, Then Placebo, Then Acetaminophen	7
Overall Study	STARTED	Aspirin First, Then Acetaminophen, Then Placebo	5
Overall Study	STARTED	Acetaminophen First, Then Placebo, Then Aspirin	7
Overall Study	STARTED	Acetaminophen First, Then Aspirin, Then Placebo	3
Overall Study	COMPLETED	Placebo First, Then Aspirin, Then Acetaminophen	5
Overall Study	COMPLETED	Placebo First, Then Acetaminophen, Then Aspirin	6
Overall Study	COMPLETED	Aspirin First, Then Placebo, Then Acetaminophen	7
Overall Study	COMPLETED	Aspirin First, Then Acetaminophen, Then Placebo	3

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Placebo	32
Total, all-cause mortality	Aspirin	31
Total, all-cause mortality	Acetaminophen	32
Total, other adverse events	Placebo	32
Total, other adverse events	Aspirin	31
Total, other adverse events	Acetaminophen	32
Total, serious adverse events	Placebo	32
Total, serious adverse events	Aspirin	31
Total, serious adverse events	Acetaminophen	32

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29076760	BACKGROUND	PubMed
33191260	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21HD091836	Aspirin before Exercise: Antipyretic pretreatment to reduce exercise-induced overheating and exhaustion in RRMS patients	LEAVITT, VICTORIA M	COLUMBIA UNIVERSITY HEALTH SCIENCES	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT	2019 to 2020

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03824938

GET https://conductscience.org/api/trials/v1/NCT03824938/registered

API reference For AI assistants